Search

Ion Beam Applications

Fermé

10.54 -1.5

Résumé

Variation du prix de l'action

24h

Actuel

Min

10.2

Max

10.8

Chiffres clés

By Trading Economics

Revenu

-10M

Ventes

206M

P/E

Moyenne du Secteur

41.111

63.778

Rendement du dividende

1.56

Marge bénéficiaire

-4.99

Employés

1,943

EBITDA

-372K

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

1.56%

2.39%

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

342M

Ouverture précédente

12.04

Clôture précédente

10.54

Ion Beam Applications Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

11 sept. 2024, 06:28 UTC

Acquisitions, Fusions, Rachats

EQT Leads $102.5 Million Series A Funding Round in Belgian Radioisotope Producer PanTera

Ion Beam Applications prévision

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Ion Beam Applications

Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates through Proton Therapy and Other Accelerators, and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or SPECT radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures. The company has strategic research and development partnership with SCK CEN (Belgian nuclear research center) to enable the production of Actinimum-225 (225Ac), a novel radioisotope for the treatment of cancer; and an agreement with University of Pennsylvania for research in ConformalFLASH. It also has a research partnership with Particle Therapy Interuniversity Center Leuven for the development of ConformalFLASH1. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.